Ideaya starts enrolling in mid-stage study of eye cancer drug; combo therapy data in 23

Doctor talking to patients are explaining the treatment of a patient

pcess609/iStock via Getty Images

Ideaya Biosciences (NASDAQ:IDYA) said it started enrollment in a phase 2 trial of darovasertib as monotherapy in neo-adjuvant and adjuvant settings in patients with primary, non-metastatic uveal melanoma (UM).

UM is a type of eye cancer.

Source link

5 Trading strategies to make money

Looking to boost your trading profits?

Get you copy of our FREE Ebook Now !!!